Back to top
more

ABM Industries (ABM)

(Delayed Data from NYSE)

$57.15 USD

57.15
510,723

+0.93 (1.65%)

Updated Aug 30, 2024 04:00 PM ET

After-Market: $57.17 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (30 out of 251)

Industry: Building Products - Maintenance Service

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Delcath Systems Stock Gains on Positive CHEMOSAT Melanoma Data

by Zacks Equity Research

DCTH's study of the CHEMOSAT Hepatic Delivery System shows that the device significantly boosts survival rates in uveal melanoma patients with liver metastases, outperforming systemic therapies.

DaVita Rallies 44% Year to Date: What's Driving the Stock?

by Zacks Equity Research

DVA's shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.

Seeking Clues to ABM Industries (ABM) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for ABM Industries (ABM), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended July 2024.

QuidelOrtho Expands in Infectious Disease Testing With New FDA Nod

by Zacks Equity Research

QDEL announces the FDA's clearance for its VITROS syphilis assay, which boosts the company's infectious disease testing portfolio.

iRhythm Technologies Launches Zio Monitoring Across Europe

by Zacks Equity Research

IRTC launches Zio monitor in Austria, Netherlands, Spain and Switzerland, which offers 14-day continuous ECG monitoring, enhancing arrhythmia diagnosis and patient care.

Are Investors Undervaluing ABM Industries (ABM) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Veeva Systems Q2 Earnings & Revenues Beat, Operating Margin Up Y/Y

by Zacks Equity Research

VEEV's fiscal second-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.

Maravai LifeSciences' Cygnus & TriLink Unveil AccuRes DNA Kits

by Zacks Equity Research

MRVI's Cygnus and TriLink introduce AccuRes kits, setting a new standard in host cell DNA quantification with unmatched sensitivity and specificity.

Accuray Stock Rises After Helix System Wins CE Mark for Cancer Care

by Zacks Equity Research

ARAY's Helix system, now CE Mark approved, aims to close global cancer care gaps with cost-effective, high-throughput radiotherapy for underserved regions.

Stryker Rallies 19.8% Year to Date: What's Driving the Stock?

by Zacks Equity Research

SYK's flagship Mako Total Knee Platform, its strategic acquisitions and a diversified product portfolio raise optimism about the stock.

AtriCure's Shares Likely to Benefit From New AtriClip Device Sales

by Zacks Equity Research

ATRC announces the treatment of the first patient using the AtriClip FLEX-Mini device.

DexCom Stock May Gain on Expanded Reach After Stelo's US Launch

by Zacks Equity Research

DXCM announces that its OTC CGM, Stelo, is now available for purchase in the United States without a prescription.

Is HealthEquity Stock a Hold Now Amid Strong Top-Line Growth?

by Zacks Equity Research

HQY's sustained strength in HSAs raises optimism about the stock.

GE Healthcare to Unveil AI-Driven Cardiac Diagnostics at ESC 2024

by Zacks Equity Research

GEHC launches AI-enhanced ultrasound and ECG-less Cardiac CT technologies, offering rapid, accurate cardiac diagnostics at the point of care.

Teleflex's (TFX) Titan SGS Stapler Showcases Positive Outcomes

by Zacks Equity Research

Teleflex (TFX) publishes an analysis of clinical data showcasing the Titan SGS Stapler's enhanced clinical outcomes and significant efficiency benefits.

Inari Medical (NARI) Issues Notice Post ClotTriever XL Recall

by Zacks Equity Research

Inari Medical (NARI) issues urgent updates to ClotTriever XL Catheter instructions following the FDA's recall after reports of serious injuries and deaths.

AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication

by Zacks Equity Research

AtriCure (ATRC) announces the receipt of an expanded CE-Mark indication for its AtriClip devices for reducing strokes in patients with Afib.

INSPIRA (IINN) CART Gets FDA Listing, to Enhance Healthcare

by Zacks Equity Research

Inspira (IINN) announces FDA listing of its INSPIRA CART, designed for use with the ART100 system, enhancing healthcare delivery during cardiopulmonary bypass.

Stryker's (SYK) Inks Deal to Aid Its Pain Management Portfolio

by Zacks Equity Research

Stryker (SYK) is set to acquire Vertos Medical to expand its interventional pain management portfolio.

Cencora (COR) Gains 16.6% YTD: What's Driving the Stock?

by Zacks Equity Research

Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.

PROCEPT BioRobotics' (PRCT) HYDROS System Gets FDA Clearance

by Zacks Equity Research

PROCEPT BioRobotics (PRCT) announces the FDA 510(k) clearance of its HYDROS Robotic System for providing better BPH treatment.

Cardinal Health (CAH) to Open New Distribution Center in Ohio

by Zacks Equity Research

Cardinal Health's (CAH) new center is set to integrate cutting-edge technology and automation, enhancing efficiency, storage capacity and quality of service.

CollPlant (CLGN), Stratasys Initiate Study for Breast Implants

by Zacks Equity Research

CollPlant (CLGN) and Stratasys announce the initiation of a pre-clinical study to focus on the ability of implants to grow natural breast tissue and completely degrade over time.

Avinger (AVGR) Launches Pantheris LV to Boost PAD Treatment

by Zacks Equity Research

Avinger (AVGR) fully launches Pantheris LV, the first image-guided atherectomy system for large vessels, thus enhancing peripheral artery disease treatment with advanced technology.

Is ABM Industries (ABM) Stock Outpacing Its Business Services Peers This Year?

by Zacks Equity Research

Here is how ABM Industries (ABM) and CRA International (CRAI) have performed compared to their sector so far this year.